Sanctuary Advisors LLC Has $1.97 Million Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Sanctuary Advisors LLC raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 26.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,825 shares of the medical equipment provider’s stock after acquiring an additional 3,776 shares during the quarter. Sanctuary Advisors LLC’s holdings in Zimmer Biomet were worth $1,965,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Dunhill Financial LLC lifted its stake in Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 218 shares during the last quarter. Ashton Thomas Securities LLC acquired a new stake in shares of Zimmer Biomet in the third quarter valued at approximately $28,000. Bangor Savings Bank bought a new position in shares of Zimmer Biomet during the 3rd quarter worth approximately $31,000. Family Firm Inc. acquired a new position in shares of Zimmer Biomet during the 2nd quarter worth approximately $33,000. Finally, Brooklyn Investment Group bought a new stake in Zimmer Biomet in the 3rd quarter valued at $35,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Down 2.0 %

Shares of Zimmer Biomet stock opened at $105.86 on Thursday. The firm’s 50-day moving average price is $107.95 and its two-hundred day moving average price is $108.53. The company has a market capitalization of $21.07 billion, a price-to-earnings ratio of 20.13, a PEG ratio of 1.96 and a beta of 1.02. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 12-month low of $101.47 and a 12-month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting the consensus estimate of $1.74. The business had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The company’s revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the business earned $1.65 earnings per share. On average, analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Monday, December 30th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.91%. Zimmer Biomet’s dividend payout ratio is currently 18.25%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research report on Thursday, October 31st. Evercore ISI decreased their price target on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Royal Bank of Canada raised their price objective on shares of Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a research report on Monday, November 4th. Wolfe Research initiated coverage on Zimmer Biomet in a research report on Tuesday, September 10th. They issued a “peer perform” rating on the stock. Finally, JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $125.00 to $128.00 in a report on Tuesday. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $123.33.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.